Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats

Molecular Medicine Reports

Volumn 4, Issue 5, 2011, Pages 811-816

  Chen, Jing ^a   Liu, Diangang ^b   Bai, Qixuan ^c   Song, Jitao ^a   Guan, Jia ^a   Gao, Jie ^a   Liu, Bingrong ^a   Ma, Xiao ^a   Du, Yaju ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Celecoxib; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Nuclear factor enhancer binding protein

Indexed keywords

AMINOTRANSFERASE; CARBOXYMETHYLCELLULOSE; CELECOXIB; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FATTY LIVER; FEEDING; HEPATITIS; HISTOPATHOLOGY; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; CYCLOOXYGENASE 2; DIET; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; LIVER; NF-KAPPA B; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; TRIGLYCERIDES;

RATTUS; RATTUS NORVEGICUS;

EID: 79960403421     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.501     Document Type: Article

References (29)

1. Mitchell JA and Warner TD: Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128: 1121-1132, 1999.
2. Suleyman H, Demircan B and Karagoz Y: Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 59: 247-258, 2007. (Pubitemid 47299726)
3. Cheng AS, Chan HL and Leung WK, et al: Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in up-regulation of COX-2. Mod Pathol 17: 1169-1179, 2004. (Pubitemid 39312943)
4. Mohammed NA, Abd El-Aleem SA, El-Hafiz HA and McMahon RF: Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol 57: 350-354, 2004. (Pubitemid 38446249)
5. Paik YH, Kim JK and Lee JI, et al: Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 58: 1517-1527, 2009.
6. Chavez E, Segovia J and Shibayama M, et al: Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. Liver Int 30: 969-978, 2010.
7. Washino Y, Koga E and Kitamura Y, et al: Effect of celecoxib, a selective cyclooxygenase-2 inhibitor on carbon tetrachloride intoxication in rats. Biol Pharm Bull 33: 707-709, 2010.
8. Yu J, Ip E and Dela PA, et al: COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 43: 826-836, 2006.
9. Larter CZ and Yeh MM: Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23: 1635-1648, 2008.
10. Fan JG and Qiao L: Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 8: 233-240, 2009.
11. Zou Y, Li J, Lu C, et al: High-fat emulsion-induced rat model of non-alcoholic steatohepatitis. Life Sci 79: 1100-1107, 2006. (Pubitemid 44102717)
12. Dela PA, Leclercq I, Field J, George J, Jones B and Farrell G: NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129: 1663-1674, 2005. (Pubitemid 41597405)
13. Ribeiro PS, Cortez-Pinto H, Sola S, et al: Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of non-alcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 99: 1708-1717, 2004. (Pubitemid 39237497)
14. Angulo P: Non-alcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
15. Farrell GC and Larter CZ: Non-alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006.
16. Day CP and James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842-845, 1998.
17. Day CP: Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16: 663-678, 2002.
18. Day CP and Saksena S: Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 17 (Suppl 3): 377-384, 2002.
19. Malaguarnera M, Di Rosa M, Nicoletti F and Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med 87: 679-695, 2009.
20. Leclercq IA, Farrell GC, Sempoux C, Dela PA and Horsmans Y: Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 41: 926-934, 2004. (Pubitemid 39575659)
21. Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH and Shih KC: COX-2-mediated inflammation in fat is crucial for obesitylinked insulin resistance and fatty liver. Obesity (Silver Spring) 17: 1150-1157, 2009.
22. Cunha NV, De Abreu SB, Panis C, et al: Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats. Life Sci 87: 375-381, 2010.
23. Yuan M, Konstantopoulos N, Lee J, et al: Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293: 1673-1677, 2001. (Pubitemid 32807849)
24. Crespo J, Cayon A, Fernandez-Gil P, et al: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in non-alcoholic steatohepatitis patients. Hepatology 34: 1158-1163, 2001. (Pubitemid 33096588)
25. Videla LA, Tapia G, Rodrigo R, et al: Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) 17: 973-979, 2009.
26. Beraza N, Malato Y, Vander BS, et al: Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 57: 655-663, 2008. (Pubitemid 351579980)
27. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
28. Alegria P, Lebre L and Chagas C: Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann Intern Med 137: 75, 2002. (Pubitemid 34705386)
29. Chamouard P, Walter P, Baumann R and Poupon R: Prolonged cholestasis associated with short-term use of celecoxib. Gastroenterol Clin Biol 29: 1286-1288, 2005. (Pubitemid 43170262)